The management of testicular cancer continues to evolve, with advances in diagnostics, risk stratification, and multimodal treatment shaping contemporary clinical practice. At the 41st Annual Congress ...
FIT-001 enrolled ccRCC patients with prior immunotherapy, KPS ≥70, and prior cabozantinib exposure, using darlifarnib 3/5/8 mg QD (7-on/7-off) plus cabozantinib 40/60 mg. Antitumor activity was ...
High-powered holmium and thulium laser platforms are expanding ureteroscopic options for complex patients, including those on anticoagulation, while emerging technologies such as Break Wave ...
Metformin consistently increased circulating Lac-Phe irrespective of disease stage, PSA response, or other tumor activity markers, indicating a metabolic signal uncoupled from antitumor efficacy in ...
In this episode of the UroOnc Minute, Wesley Yip, MD, joins host Adam B. Weiner, MD, to discuss key takeaways from LITESPARK-022, exploring the role for adjuvant pembrolizumab plus belzutifan in ...
CMS established permanent HCPCS J9183 for Inlexzo to support standardized claims submission and potentially reduce reimbursement-driven access delays across government and commercial payers starting ...
The first patients have been treated in WOLVERINE, a prospective feasibility trial of the Edison Histotripsy System for BPH. The first patients have been treated in the WOLVERINE study (NCT07214675), ...
FDA 510(k) clearance enables use of external neuromuscular stimulation to strengthen pelvic floor musculature and improve bladder control in men with post-prostatectomy incontinence. Daily home ...
Noninvasive, anesthesia-free Break Wave ultrasound lithotripsy received 510(k) clearance, supported by the SOUND pivotal trial, and can pair with Stone Clear to aid fragment clearance. VYBRIQUE, an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results